Phase III PEG-Intron in HIV-infected Patients (Study P00738)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00035360|
Recruitment Status : Completed
First Posted : May 6, 2002
Last Update Posted : March 10, 2017
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections AIDS||Drug: PEG-Intron||Phase 3|
This study will randomize 675 patients (225 in each of the 3 arms) to either: PEG-Intron 1mcg; 3mcg or Placebo, at 90 centers worldwide. Each center will enroll approximately 10 patients.
Study drug will be added to optimized background anti-retroviral therapy of patients whose HIV RNA is incompletely suppressed by their therapy (HIV RNA 400-50,000 copies/ML) after 2-6 months.
A single dose reduction of 50% will be allowed for toxicity. An Interim Analysis will be conducted when 50% of patients have completed 24 weeks of therapy. The study treatment phase will be 48 weeks with monthly visits for virologic virologic and safety monitoring. The primary endpoint is change in HIV RNA from baseline to week to assess efficacy. Durability of response will be assessed at 48 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||49 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase 3 Study of PEG-Intron in Heavily Treatment-experienced, HIV-infected Patients|
|Study Start Date :||March 2002|
|Actual Primary Completion Date :||October 2003|
|Actual Study Completion Date :||October 2003|